Summary:
Click image to enlargeA Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1
Qualified Participants Must:
• Has been diagnosed for Psoriatic Arthritis
•
Subject has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) to previous or current treatment with at least 1 non-biologic DMAR
•
18 years of age or older
Qualified Participants May Receive:
Study related care, medications and labs at no cost
Compensation of time and travel of $50 for completed study visits